Year: 2020

news_6

Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company’s Investigational Treatment for Contact Lens Discomfort

Significant improvement in multiple measures of Meibomian gland secretion and associated improvements in contact lens wear time TEL AVIV, Israel...

news_6

Regenacy Announces the Formation of a Joint Venture with 3E Bioventures to Develop Ricolinostat in China and the Start of a U.S. Phase 2 Study in Painful Diabetic Peripheral Neuropathy

WALTHAM, Mass.--(BUSINESS WIRE)--Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, and 3E Bioventures...

news_6

Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Legend Biotech also achieves fifth milestone payment under its collaboration agreement with Janssen in clinical development of cilta-cel SOMERSET, N.J.--(BUSINESS...